B. Riley Securities Initiates Coverage of Denali Therapeutics (DNLI) with Buy Recommendation
Nasdaq Fintel reports that on September 6, 2023, B. Riley Securities initiated coverage of Denali Therapeutics (NASDAQ:DNLI) with a Buy recommendation.
Analyst Price Forecast Suggests 134.79% Upside
As of August 31, 2023, the average one-year price target for Denali Therapeutics is 57.99. The forecasts range from a low of 26.26 to a high of $110.25. The average price target represents an increase of 134.79% from its latest reported closing price of 24.70.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Denali Therapeutics is 89MM, a decrease of 74.07%. The projected annual non-GAAP EPS is -3.14.
What is the Fund Sentiment?
There are 440 funds or institutions reporting positions in Denali Therapeutics. This is unchanged over the last quarter. Average portfolio weight of all funds dedicated to DNLI is 0.23%, a decrease of 0.25%. Total shares owned by institutions increased in the last three months by 0.64% to 115,637K shares. The put/call ratio of DNLI is 0.15, indicating a bullish outlook.